All In MedTech

Device Trial Radar · NCT05260281

Performance Evaluation of Artificial Intelligence Assisted Diabetic Retinopathy Grading in the Leuven University Hospital: Can Technology Improve the Resident?

Last checked: Nov 19, 2026Latest source record: Mar 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

139

Planned (sponsor's estimate)

Start

Mar 1, 2022

Primary completion

Aug 1, 2022

Study completion Nov 1, 2022

Sponsor

Lead sponsor
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 2, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the added value of the use of artificial intelligence in the diagnosis of referable diabetic retinopathy in a teaching hospital setting

Conditions

  • To Evaluate the Added Value of the Use of Artificial Intelligence in the Diagnosis of Referable Diabetic Retinopathy in a Teaching Hospital Setting

Interventions

  • MONA algorithmDevice

    most artificial intelligence algorithms, like the MONA algorithm used in this study, are trained on 45-degree fundus photographs. In order to incorporate the use of the algorithm, the study intervention consists of taking 1 extra 45-degree fundus photograph per eye per patient using the Zeiss Cirrus Photo 800 system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. does AI augment diagnostic performance of residentTime frame: 4 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.